Evidence map›Paper›PMID 39542518›Full record

ArticleBrain tumor research and treatment2024

Determination of Optimal Treatment Plan for Papillary Tumor of the Pineal Region: Case Series With Literature Review.

Brandi W Pang, David J Mazur-Hart, Nasser K Yaghi, Seunggu Jude Han, Jesse J Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Pineal Gland Parenchyma Tumors.Advances and technical standards in neurosurgery · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brandi W PangDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0002-8959-1833
David J Mazur-HartDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0003-3950-6685
Nasser K YaghiDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0003-0810-8502
Seunggu Jude HanDepartment of Neurological Surgery, Stanford University, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0002-6944-3745
Jesse J LiuDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. liu@ohsu.edu.ORCID https://orcid.org/0000-0001-5819-7860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPapillary tumor of the pineal region (PTPR) is a rare neuroepithelial tumor with Central Nervous System (CNS) World Health Organization (WHO) grade II or III classification. Due to its rarity, there is no clear census on treatment. The purpose of this study is to identify the optimal treatment plan focused on extending overall survival (OS).

methodsThis is an institutional case series with review of the literature. Fifty-three publications were analyzed. Only cases with histological diagnosis of PTPR were included. Data collected included demographics, treatment modalities, disease progression, and OS.

resultsThe analysis included 105 patients from the literature and 3 new cases (54 female, 50%) with an average age of 33.1 years (range 1-73 years). The average lesion size was 26.4 mm (range 5-50 mm) in longest axis. All patients underwent an initial resection. There were 46 cases of surgery alone. The remaining cases received adjuvant therapy including radiation (RT), stereotactic radiosurgery (SRS), chemotherapy (CT), or RT and CT. The average follow-up was 61.4 months (range 1-240 months). OS at 1 year was 96.9%, at 5 years was 87.5%, and at 10 years was 80.2%. Overall progression-free survival (PFS) was 57.4%. Statistical significance was observed in PFS in the surgery plus SRS group and surgery plus CT and RT group. Surgery with SRS had the best PFS (75%), and OS at 1 year (100%) and 5 years (88.9%). Surgery with CT and RT had the best OS at 10 years (85.7%).

conclusionWe describe a case series and literature review of PTPR to help guide the most effective treatment strategies for this rare disease entity. We recommend surgery followed by SRS as the treatment of choice because of its best PFS and 5-year survival rates. We would also recommend adding chemotherapy in the event of disease progression or recurrence as adjuvant radiation and chemotherapy provided the best 10-year survival.

Indexed as

Brain tumorMedical oncologyNeurological surgeryPineal tumorRadiation oncologyRadiosurgery

Identifiers

PMID39542518
PMCPMC11570082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.